May 15, 2008 - Daiichi Sankyo, Inc., announced that data presented at the American Society of Hypertension's Twenty-Third Annual Scientific Meeting (ASH 2008) in New Orleans demonstrated that the powerful combination drug AZOR™ (amlodipine and olmesartan medoxomil) safely and effectively helped patients across several major subpopulations lower their blood pressure (BP). An analysis of patient subgroups from the pivotal registrational trial demonstrated the efficacy of AZOR in several key difficult to treat patient groups including people of African and Hispanic/Latino decent, people with high body mass index (BMI) and those with diabetes... [PDF] Daiichi Sankyo's Press Release -
Friday, May 30, 2008
Daiichi Sankyo : AZOR Reduces Blood Pressure in Difficult to Treat Special Populations
May 15, 2008 - Daiichi Sankyo, Inc., announced that data presented at the American Society of Hypertension's Twenty-Third Annual Scientific Meeting (ASH 2008) in New Orleans demonstrated that the powerful combination drug AZOR™ (amlodipine and olmesartan medoxomil) safely and effectively helped patients across several major subpopulations lower their blood pressure (BP). An analysis of patient subgroups from the pivotal registrational trial demonstrated the efficacy of AZOR in several key difficult to treat patient groups including people of African and Hispanic/Latino decent, people with high body mass index (BMI) and those with diabetes... [PDF] Daiichi Sankyo's Press Release -
